John P. Butler

CIK: 0001591467

Transaction Breakdown

Open Market Buys (P)1 (8.3%)

High conviction signal

Open Market Sales (S)7 (58.3%)

Position reduction

Option Exercises (M)1 (8.3%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AKBA

Akebia Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

AKBA
Akebia Therapeutics, Inc.
Aug 6, 2026
Exercise(M)
Direct
350K shares at avg. $0.63$221K
AKBA
Akebia Therapeutics, Inc.
Mar 4, 2026
Purchase(P)
Direct
69.3K shares at avg. $1.25$87K
AKBA
Akebia Therapeutics, Inc.
Feb 2, 2026
Award(A)
Direct
175.3K shares at avg. $1.41$247K
AKBA
Akebia Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
114.9K shares at avg. $1.39$160K
AKBA
Akebia Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
46.7K shares at avg. $1.39$65K
AKBA
Akebia Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
83.7K shares at avg. $1.39$116K
AKBA
Akebia Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
96.1K shares at avg. $1.39$134K
AKBA
Akebia Therapeutics, Inc.
Jan 30, 2026
Award(A)
Direct
743K shares-
AKBA
Akebia Therapeutics, Inc.
Mar 3, 2025
Sale(S)
Direct
46.4K shares at avg. $1.83$85K
AKBA
Akebia Therapeutics, Inc.
Feb 3, 2025
Sale(S)
Direct
98K shares at avg. $2.10$206K
AKBA
Akebia Therapeutics, Inc.
Feb 3, 2025
Sale(S)
Direct
46.3K shares at avg. $2.10$97K
AKBA
Akebia Therapeutics, Inc.
Jan 31, 2025
Award(A)
Direct
701K shares-

		Type	Shares	Price		Ownership
Aug 6, 2026	AKBA Akebia Therapeutics, Inc.	Exercise(M)	350,000	$0.63	$220,500	Direct
Mar 4, 2026	AKBA Akebia Therapeutics, Inc.	Purchase(P)	69,270	$1.25	$86,588	Direct
Feb 2, 2026	AKBA Akebia Therapeutics, Inc.	Award(A)	175,250	$1.41	$247,103	Direct
Feb 2, 2026	AKBA Akebia Therapeutics, Inc.	Sale(S)	114,891	$1.39	$159,698	Direct
Feb 2, 2026	AKBA Akebia Therapeutics, Inc.	Sale(S)	46,660	$1.39	$64,857	Direct
Feb 2, 2026	AKBA Akebia Therapeutics, Inc.	Sale(S)	83,689	$1.39	$116,328	Direct
Feb 2, 2026	AKBA Akebia Therapeutics, Inc.	Sale(S)	96,065	$1.39	$133,530	Direct
Jan 30, 2026	AKBA Akebia Therapeutics, Inc.	Award(A)	743,000	-	$0	Direct
Mar 3, 2025	AKBA Akebia Therapeutics, Inc.	Sale(S)	46,409	$1.83	$84,928	Direct
Feb 3, 2025	AKBA Akebia Therapeutics, Inc.	Sale(S)	97,982	$2.10	$205,762	Direct
Feb 3, 2025	AKBA Akebia Therapeutics, Inc.	Sale(S)	46,268	$2.10	$97,163	Direct
Jan 31, 2025	AKBA Akebia Therapeutics, Inc.	Award(A)	701,000	-	-	Direct

1-12 of 12 transactions

About Butler John P.

Butler John P. (SEC CIK 0001591467) files insider reports with the SEC as CEO and President of Akebia Therapeutics, Inc. (AKBA).

Signal8 holds 6 ownership filings by Butler John P., all Form 4s, filed between Feb 4, 2025 and Aug 10, 2026. Those filings report 12 transactions, from Jan 31, 2025 to Aug 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Butler John P.'s filings is in CAMBRIDGE, MA.

Recent filings by Butler John P.

Aug 6, 2026: Option exercise of AKBA shares (Form 4, code M).
Mar 4, 2026: Open-market purchase of AKBA shares (Form 4, code P).
Feb 2, 2026: Grant or award of AKBA shares (Form 4, code A).
Feb 2, 2026: Open-market sales of AKBA shares (4 lines, Form 4, code S).
Jan 30, 2026: Grant or award of AKBA shares (Form 4, code A).

Other insiders filing for Akebia Therapeutics, Inc. (AKBA)

Ostrowski Erik, SVP, CFO, CBO & Treasurer
Wolf Myles, Director
Smith Cynthia, Director
ROGERS MICHAEL W, Director
FRIESON RON, Director
ZUMWALT LEANNE M, Director

How to read Form 4 transaction codes